Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Although usually referred to as a structural actin-binding protein, LIM and SH3 domain-containing protein may actually be dynamically involved in the control of a wide spectrum of cellular processes, by virtue of its interaction with several molecular partners. Alongside being ubiquitously expressed in physiological conditions, LIM and SH3 domain-containing protein is overexpressed in a growing number of human cancers, in which it may actively contribute to their aggressiveness by promoting cell proliferation and migration. In view of the recent findings, implicating the protein in cancer progression, we discuss here the most relevant discoveries highlighting the role of this versatile protein in various human tumors. The correlation between LIM and SH3 domain-containing protein expression levels in cancer and the poor outcome and metastatic behavior of tumors denotes the clinical significance of this protein and hints its potential value as a new cancer prognostic or even diagnostic biomarker. This may be decisive not only to optimize existing pharmacological regimes but also to delineate novel, more efficacious therapeutic and/or preventive approaches.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1010428317705757 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
and are Candidate MicroRNA Regulators in Multiple Sclerosis.
Iran J Med Sci
July 2025
Department of Genetics, Department of Obstetrics, Gynecology, and Reproductive Sciences, and Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Background: An incapacitating chronic inflammatory neurodegenerative illness, known as multiple sclerosis (MS), is characterized by lymphocyte infiltration into the central nervous system. We aimed to identify specific miRNAs whose altered expression correlates with MS diagnosis and therapy selection, which could be biomarkers for these aspects of the disease.
Methods: The GSE21079 dataset was obtained for this study using Geoquery version 2.
CXCR4-LASP1-G9a-SNAIL axis drives NEPC transdifferentiation via induction of EMT and downregulation of REST.
Cell Genom
August 2025
Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada. Electronic address:
Phenotypic switching is an emerging driver of cancer treatment resistance, yet early signals regulating this process remain unclear. Here, using longitudinal single-cell RNA sequencing, we mapped differentiation trajectories in the LTL331 prostate adenocarcinoma patient-derived xenograft (PDX) model undergoing neuroendocrine prostate cancer (NEPC) transformation post castration. Our analyses identified a key differentiation node marked by epithelial-mesenchymal transition (EMT) and repressor element-1 silencing transcription factor (REST) downregulation driven by the CXCR4-LASP1-G9a-SNAIL axis.
View Article and Find Full Text PDFDAB2 binds to LASP1 to participate in migration and invasion of non-small cell lung cancer through TGF-β/Smad pathway.
J Formos Med Assoc
May 2025
Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, University of South China, China. Electronic address:
Background: Disabled homolog 2 (DAB2) and LIM and Src homology 3 region (SH3) domain protein 1 (LASP1) have been shown to play a role in the course of non-small cell lung cancer (NSCLC). However, the specific regulatory mechanism remains to be elucidated. The aim of this work was to investigate the role and interaction between DAB2 and LASP1 in the development of NSCLC.
View Article and Find Full Text PDFEngineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy.
Cancer Res
May 2025
Department of Virology, University of Helsinki, Helsinki, Finland.
Engineered T-cell therapies have emerged as a promising approach for cancer treatment, yet their application to solid tumors remains challenging because of the limited specificity and persistence of current antigen recognition strategies. In this study, we introduce sherpabodies, engineered from a human SH3 domain scaffold, as a class of antibody-mimetic proteins capable of precise tumor-associated antigen (TAA) recognition. A phage display library identified sherpabodies against a panel of popular TAAs, which were subsequently incorporated into second-generation chimeric antigen receptor (CAR) constructs that were termed sherpabody-guided CARs (SbCAR).
View Article and Find Full Text PDFLIM and SH3 protein 2 (Lasp2) is a novel pregnane X receptor target gene in mouse liver.
Mol Pharmacol
March 2025
Research Unit of Biomedicine and Internal Medicine, Biocenter Oulu, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland. Electronic address:
LIM and Src homology 3 (SH3) protein 2 (LASP2) is a small focal adhesion protein first identified as a splice variant of the nebulette gene (Nebl). As the newest member of the nebulin protein family, the regulation and function of LASP2 remain largely unknown. Our previous RNA-sequencing results identified Nebl as one of the most highly induced genes in the mouse liver in response to the activation of pregnane X receptor (PXR).
View Article and Find Full Text PDF